Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.

Experimental hematology - 1 Sept 1996

MacIntyre A R, Christmas S E, Clark R E

Abstract excerpt

Chronic myelogenous leukemia (CML) is characterized by a t(9;22) chromosomal translocation resulting in the expression of a novel bcr-abl fusion protein. The region spanning the fusion point is novel to the immune system and hence represents a potential leukemia-specific antigen. The ability of a 21-mer b3a2 fusion peptide to induce an in vitro lymphoproliferative response in a panel of 54 normal donors has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Amino Acid Sequence
Share to Cell Division

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cells, Cultured

Share to Histocompatibility Antigens Class II

Share to Lymphocyte Activation

Share to Lymphocytes

Share to Molecular Sequence Data

Source

Identifiers

PMID: 8862441

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.PMID 8862441Read ↗

Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptideSemantic proximity Read ↗

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.Semantic proximity Read ↗

HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.Semantic proximity Read ↗

Specific binding of leukemia oncogene fusion protein peptides to HLA class I moleculesSemantic proximity Read ↗

T-cell responses in chronic myeloid leukaemiaSemantic proximity Read ↗

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemiaSemantic proximity Read ↗

Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).Semantic proximity Read ↗

Human leukocyte antigens in Indian patients with chronic myeloid leukemia.Semantic proximity Read ↗

Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.